JP2015533510A5 - - Google Patents

Download PDF

Info

Publication number
JP2015533510A5
JP2015533510A5 JP2015539817A JP2015539817A JP2015533510A5 JP 2015533510 A5 JP2015533510 A5 JP 2015533510A5 JP 2015539817 A JP2015539817 A JP 2015539817A JP 2015539817 A JP2015539817 A JP 2015539817A JP 2015533510 A5 JP2015533510 A5 JP 2015533510A5
Authority
JP
Japan
Prior art keywords
retrovirus
promoter
cancer
pharmaceutical composition
retroviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015539817A
Other languages
English (en)
Japanese (ja)
Other versions
JP6419706B2 (ja
JP2015533510A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/066709 external-priority patent/WO2014066700A1/en
Publication of JP2015533510A publication Critical patent/JP2015533510A/ja
Publication of JP2015533510A5 publication Critical patent/JP2015533510A5/ja
Application granted granted Critical
Publication of JP6419706B2 publication Critical patent/JP6419706B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015539817A 2012-10-25 2013-10-24 ミニプロモーターカセットを含むレトロウイルスベクター Expired - Fee Related JP6419706B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718610P 2012-10-25 2012-10-25
US61/718,610 2012-10-25
PCT/US2013/066709 WO2014066700A1 (en) 2012-10-25 2013-10-24 Retroviral vector with mini-promoter cassette

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018128726A Division JP2018183155A (ja) 2012-10-25 2018-07-06 ミニプロモーターカセットを含むレトロウイルスベクター

Publications (3)

Publication Number Publication Date
JP2015533510A JP2015533510A (ja) 2015-11-26
JP2015533510A5 true JP2015533510A5 (https=) 2016-11-10
JP6419706B2 JP6419706B2 (ja) 2018-11-07

Family

ID=50545284

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015539817A Expired - Fee Related JP6419706B2 (ja) 2012-10-25 2013-10-24 ミニプロモーターカセットを含むレトロウイルスベクター
JP2018128726A Pending JP2018183155A (ja) 2012-10-25 2018-07-06 ミニプロモーターカセットを含むレトロウイルスベクター
JP2020136906A Pending JP2021006031A (ja) 2012-10-25 2020-08-14 ミニプロモーターカセットを含むレトロウイルスベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018128726A Pending JP2018183155A (ja) 2012-10-25 2018-07-06 ミニプロモーターカセットを含むレトロウイルスベクター
JP2020136906A Pending JP2021006031A (ja) 2012-10-25 2020-08-14 ミニプロモーターカセットを含むレトロウイルスベクター

Country Status (6)

Country Link
US (1) US11065311B2 (https=)
EP (2) EP3623478A1 (https=)
JP (3) JP6419706B2 (https=)
CN (1) CN104884627A (https=)
ES (1) ES2786051T3 (https=)
WO (1) WO2014066700A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11230719B2 (en) * 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
AU2016317936A1 (en) * 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
AU2016355468B2 (en) * 2015-11-20 2022-12-15 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
EP3380604B1 (en) * 2015-11-24 2022-12-28 GlaxoSmithKline Intellectual Property Development Limited Stable cell lines for retroviral production
CN110225977B (zh) 2016-11-29 2023-05-05 阿迪雷尔有限公司 基因治疗载体系统和药物前体基因
CA3063464A1 (en) 2017-05-19 2018-11-22 Encoded Therapeutics, Inc. High activity regulatory elements
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
IL274926B2 (en) 2017-12-01 2026-04-01 Encoded Therapeutics Inc Pyrazolopyrimidines with activity against respiratory syncytial virus
GB201720948D0 (en) * 2017-12-15 2018-01-31 Autolus Ltd Plasmid system
EP3880829A4 (en) * 2018-11-13 2022-08-24 Denovo Biopharma LLC RECOMBINANT VECTORS INCLUDING GENES FOR BINDING DOMAINS AND SECRETABLE PEPTIDES
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
JP2023511717A (ja) * 2020-01-30 2023-03-22 パーデュー・リサーチ・ファウンデーション 治療用タンパク質のリガンド媒介性送達およびその使用
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之pd-l1結合多肽
JP2025515486A (ja) 2022-04-29 2025-05-15 ピュリノミア バイオテック, インコーポレイテッド 好酸球駆動性疾患及び障害を治療するための方法及び組成物
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN116334010B (zh) * 2023-05-30 2023-08-29 中义(北京)健康研究院 一种重组单纯疱疹病毒及其制备方法和应用
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5997859A (en) 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
ATE118247T1 (de) 1988-09-27 1995-02-15 Dana Farber Cancer Inst Inc Vektor, der ein replikationskompetentes hiv-i- provirus und ein heterologes gen enthält.
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
JP3378962B2 (ja) 1991-08-07 2003-02-17 アンダースン,ダブリュー.,フレンチ 内部リボソームエントリー部位を含むレトロウイルスベクター
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
EP0746625B1 (en) 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targetable vector particles
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
WO1994023048A2 (en) 1993-04-06 1994-10-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gibbon ape leukemia virus-based retroviral vectors
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
JP4046349B2 (ja) 1994-11-07 2008-02-13 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 腫瘍壊死因子−γ
US20030157070A1 (en) 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6117681A (en) 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
WO1996034095A1 (en) 1995-04-27 1996-10-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
GB9604354D0 (en) 1996-02-29 1996-05-01 Isis Innovation Targeting adapters
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
ES2316153T3 (es) 1996-08-16 2009-04-01 Human Genome Sciences, Inc. Endoquina alfa humana.
ES2308787T3 (es) 1996-08-16 2008-12-01 Schering Corporation Antigenos de superficie de celular de mamiferos; reactivos relacionados.
US6025192A (en) 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
ES2248823T5 (es) 1996-10-25 2011-11-03 Human Genome Sciences, Inc. Neutroquina alfa.
US6261801B1 (en) 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
US6342363B1 (en) 1997-01-28 2002-01-29 Human Genome Sciences, Inc. Death domain containing receptor 4 nucleic acids and methods
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
CA2292790A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
WO1998056892A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
AU1334999A (en) 1997-10-20 1999-05-10 Universita Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
FR2773561A1 (fr) 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
US6451304B1 (en) 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
CA2327444A1 (en) 1998-04-29 1999-11-04 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
FR2778670B1 (fr) 1998-05-18 2002-12-13 Rhone Poulenc Rorer Sa Methodes et compositions pour la production de particules virales
GB9810752D0 (en) 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
WO1999060110A2 (en) 1998-05-20 1999-11-25 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
ES2323744T3 (es) 1998-10-01 2009-07-23 University Of Southern California Sistema retroviral de suministro de genes y metodos de uso.
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
GB0122803D0 (en) * 2001-09-21 2001-11-14 Oxford Biomedica Ltd Vector
US6576463B1 (en) 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
WO2000066758A1 (en) 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
EP1059357A1 (en) 1999-06-09 2000-12-13 Universite Pierre Et Marie Curie Paris Vi Replicating or semi-replicating retroviral constructs, preparation and uses for gene delivery
EP1059356B1 (en) 1999-06-09 2005-11-02 Universite Pierre Et Marie Curie Paris Vi Replicating retroviral constructs, preparation and uses for gene delivery
GB2368846B (en) 1999-07-08 2004-08-25 Univ California Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use
WO2001040488A1 (en) 1999-11-30 2001-06-07 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
US6322696B1 (en) 2000-02-25 2001-11-27 Gp Companies, Inc. Inlet filter for high pressure sprayer
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
WO2002022663A2 (en) 2000-09-18 2002-03-21 Maxygen, Inc. Stress resistant retroviruses
GB0024550D0 (https=) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
WO2002042482A2 (en) 2000-11-27 2002-05-30 Chiron Corporation Functional lentiviral vector from an mlv-based backbone
US7226779B2 (en) 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
CA2442144A1 (en) 2001-03-26 2002-11-21 The Board Of Trustees Of The Leland Stanford Junior University A helper dependent adenoviral vector system and methods for using the same
US7211247B2 (en) 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
JP2002335965A (ja) 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
AU2002342151B2 (en) 2001-10-26 2007-07-19 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
FR2832424B1 (fr) 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations
US20030121068A1 (en) 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
WO2003064666A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
WO2003097674A1 (en) 2002-05-17 2003-11-27 Pipeline Biotech A/S A purified polypeptide, isolated nucleic acids encoding said polypeptide, vectors and use thereof
JP2005532814A (ja) 2002-07-17 2005-11-04 ブリストル−マイヤーズ スクイブ カンパニー アンドロゲン応答配列の制御下にレポーター核酸を発現するトランスジェニック非ヒト哺乳動物
JP4992032B2 (ja) 2002-09-03 2012-08-08 オックスフォード バイオメディカ(ユーケー)リミテッド レトロウイルスベクター
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005118802A2 (en) 2004-06-03 2005-12-15 The Regents Of The University Of California Targeting pseudotyped retroviral vectors
US20070003522A1 (en) 2004-07-08 2007-01-04 Albritton Lorraine M Methods and compositions for improved retroviral gene and drug delivery
RU2007114111A (ru) 2004-11-04 2008-12-10 Пфайзер Продактс Инк. (Us) Лечение рака молочной железы с помощью комбинации антитела против ctla4 и ингибитора ароматазы
AU2005309485A1 (en) 2004-11-24 2006-06-01 Nanovector Limited Viral vectors
US20060147429A1 (en) 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
WO2006127980A2 (en) * 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
JP2007054069A (ja) 2005-08-24 2007-03-08 Medizinische Hochschule Hannover 自己不活性化レトロウイルスベクター
WO2007036233A2 (en) 2005-09-30 2007-04-05 Zgene A/S Dekkera/brettanomyces cytosine deaminases and their use
WO2007041350A2 (en) 2005-10-01 2007-04-12 Charles Stout Regulatable fusion promoters
US8034355B2 (en) 2005-10-07 2011-10-11 Presidents And Fellows Of Harvard College Attenuated nonsegmented negative-sense RNA viruses with reduced mRNA cap methyltransferase activity comprising mutations within conserved domain VI of the large polymerase
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
EP2487258B1 (en) 2006-01-05 2014-10-01 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer
WO2007095201A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California Pseudotyped retroviral vectors and methods of use thereof
WO2007107156A2 (en) 2006-03-17 2007-09-27 Aarhus Universitet Chimeric viral envelopes
PT2012816E (pt) 2006-05-02 2012-08-17 Sigma Tau Ind Farmaceuti Uso de timosina 1, isolada ou em combinação com ptx3 ou ganciclovir, para o tratamento da infeção por citomegalovírus
BRPI0714495B8 (pt) 2006-07-21 2021-05-25 California Inst Of Techn lentivírus deficiente para replicação recombinante pseudotipado
WO2008151633A2 (en) 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
MX337213B (es) 2008-06-30 2016-02-17 Tocagen Inc Formulaciones de 5-fluorocitosina y usos de las mismas.
CA2738472A1 (en) 2008-09-26 2010-04-22 Tocagen Inc. Gene therapy vectors and cytosine deaminases
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
DK2443242T3 (en) 2009-06-17 2017-01-30 Tocagen Inc Production cells for replicative retroviral vectors
CN103237894A (zh) * 2010-08-13 2013-08-07 先锋国际良种公司 包含具有羟基苯丙酮酸双加氧酶(hppd)活性的序列的组合物和方法
WO2012058673A2 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
KR101888391B1 (ko) 2014-09-01 2018-08-14 삼성전자 주식회사 음성 신호 관리 방법 및 이를 제공하는 전자 장치

Similar Documents

Publication Publication Date Title
JP2015533510A5 (https=)
US11065311B2 (en) Retroviral vector with mini-promoter cassette
US20220195460A1 (en) Retroviral vector having immune-stimulating activity
JP4663943B2 (ja) 免疫治療組成物調製用のレンチウイルスベクター
CN1058993C (zh) 用于癌症治疗的分子嵌合体的制备方法及应用
JP2012503987A5 (https=)
ES2709481T3 (es) Vectores recombinantes
JP2016526920A5 (https=)
JP2012503986A5 (https=)
ES2911448T3 (es) Vectores combinados y métodos para el tratamiento del cáncer
CN105579581A (zh) 具有优化的a凸出物的重组载体
JP2018526007A (ja) 2aペプチドを含む組換えベクター
AU2011278931A1 (en) Targeted nanoparticles for cancer and other disorders
JP2009112314A (ja) 疾患を処置するための方法および組成物
US20070178066A1 (en) Pathotropic targeted gene delivery system for cancer and other disorders
CN109072253B (zh) 包含GM-CSF基因、Flt3L-TRAIL融合基因、抑制TGF-β表达的shRNA和抑制HSP表达的shRNA的抗肿瘤组合物
JP4343708B2 (ja) 改良型キメラ糖タンパク質と、類型化されたレンチウイルス
US20160222412A1 (en) Recombinant vector with stabilizing a-loop
US20240167038A1 (en) RNA Trans-Splicing Molecule